Weekly Spotlight - 07.11.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

In the News

Autoimmune Liver Disease Unveiled by Tuberculosis Treatment: Two Case Reports

This article presents two cases of autoimmune liver disease emerging during tuberculosis treatment, highlighting the challenge of distinguishing drug-induced liver injury from underlying autoimmune conditions. It underscores the importance of considering autoimmune liver disease when liver complications arise during anti-TB drug therapy.

Patient Advocacy and Scientific Progress at EASL Congress 2024

The 2024 EASL Congress showcased a strong blend of scientific discussion and patient advocacy. As a patient representative, the focus was on addressing stigma and providing updates on Alpha-1 antitrypsin deficiency. Engaging with hepatologists at the ERN RARE LIVER booth emphasized the vital role of advocacy in advancing the field.

Future Therapies for Autoimmune Hepatitis Explored at International Workshop

The 1st International Workshop on Future Therapies in Autoimmune Hepatitis gathered experts to discuss current treatments and the development of new approaches. A planned multicenter trial aims to improve patient outcomes, marking a significant step toward advancing the understanding and management of this rare liver disease.

Zetomipzomib Safe in Autoimmune Hepatitis Phase 2a Trial, Study Continues

Zetomipzomib, a potential treatment for autoimmune hepatitis, has successfully passed its Phase 2a safety trial with no major safety concerns. The ongoing study will now focus solely on autoimmune hepatitis, with top-line results expected in 2025, offering hope for improved treatment options in the future.